| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.29 | 2e-08 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.16 | 3e-07 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.25 | 1e-06 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.15 | 4e-06 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.15 | 4e-06 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.13 | 2e-05 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.2 | 2e-05 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.14 | 6e-05 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.14 | 9e-05 |